Using minocycline to treat brain inflammation and cognitive issues in sickle cell disease
Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease
This study is looking at how inflammation in the brain affects thinking and behavior in people with sickle cell disease, and it will test a possible treatment called minocycline to see if it can help improve these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10993156 on NIH RePORTER |
What this research studies
This research investigates how neuroinflammation contributes to cognitive and behavioral deficits in patients with sickle cell disease (SCD). It aims to understand the relationship between neuroinflammation and cognitive decline, focusing on the role of small molecules like minocycline as potential treatments. By studying sickle cell mice, the researchers will explore how these cognitive issues develop over time and identify strategies to prevent or treat them. Patients may be involved in trials assessing the effectiveness of these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience cognitive or behavioral deficits.
Not a fit: Patients without sickle cell disease or those who do not exhibit cognitive or behavioral issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cognitive function and quality of life for patients with sickle cell disease.
How similar studies have performed: Other research has shown promise in using similar approaches to address cognitive deficits related to neuroinflammation, suggesting potential for success in this area.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Hyacinth, Hyacinth Idu — University of Cincinnati
- Study coordinator: Hyacinth, Hyacinth Idu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.